Drugs / Changkang Granule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04492787 | Jul 2020 → Apr 2022 | irritable bowel syndrome | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Changkang Granule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04492787 ↗ |